These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3117305)

  • 1. Aluminium bone disease in patients receiving plasma exchange with contaminated albumin.
    Maharaj D; Fell GS; Boyce BF; Ng JP; Smith GD; Boulton-Jones JM; Cumming RL; Davidson JF
    Br Med J (Clin Res Ed); 1987 Sep; 295(6600):693-6. PubMed ID: 3117305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aluminium bone deposits in normal renal function patients after long-term treatment by plasma exchange.
    Mousson C; Charhon SA; Ammar M; Accominotti M; Rifle G
    Int J Artif Organs; 1989 Oct; 12(10):664-7. PubMed ID: 2807593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical study of concerning factors of decreased bone mineral content in hemodialysis patients].
    Kohara N
    Nihon Jinzo Gakkai Shi; 1991 Jun; 33(6):587-96. PubMed ID: 1920939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response relationships in aluminium toxicity in humans.
    Coulson JM; Hughes BW
    Clin Toxicol (Phila); 2022 Apr; 60(4):415-428. PubMed ID: 35179097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone aluminum deposition in maintenance dialysis patients treated with aluminium-free dialysate: role of aluminium hydroxide consumption.
    Heaf JG; Pødenphant J; Andersen JR
    Nephron; 1986; 42(3):210-6. PubMed ID: 3945361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum aluminium concentration and aluminium deposits in bone in patients receiving haemodialysis.
    Charhon SA; Chavassieux PM; Meunier PJ; Accominotti M
    Br Med J (Clin Res Ed); 1985 Jun; 290(6482):1613-4. PubMed ID: 3924189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone aluminium in haemodialysed patients and in rats injected with aluminium chloride: relationship to impaired bone mineralisation.
    Ellis HA; McCarthy JH; Herrington J
    J Clin Pathol; 1979 Aug; 32(8):832-44. PubMed ID: 389958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aluminum load in chronic intermittent plasma exchange.
    Wilhelm M; Sprenger KB; Vossas U; Ohnesorge FK
    J Toxicol Clin Toxicol; 1987; 25(3):209-20. PubMed ID: 3612899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of deferoxamine in the management of aluminum accumulation in bone in patients with renal failure.
    Malluche HH; Smith AJ; Abreo K; Faugere MC
    N Engl J Med; 1984 Jul; 311(3):140-4. PubMed ID: 6377067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity?
    Jenkins DA; Gouldesbrough D; Smith GD; Cowie JF; Winney RJ
    Nephrol Dial Transplant; 1989; 4(1):51-6. PubMed ID: 2494599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of fracturing renal osteodystrophy by desferrioxamine.
    Ackrill P; Day JP; Garstang FM; Hodge KC; Metcalfe PJ; Benzo Z; Hill K; Ralston AJ; Ball J; Denton J
    Proc Eur Dial Transplant Assoc; 1983; 19():203-7. PubMed ID: 6878234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of desferrioxamine infusion test for bone aluminium deposits in hemodialyzed patients.
    Berland Y; Charhon SA; Olmer M; Meunier PJ
    Nephron; 1985; 40(4):433-5. PubMed ID: 4022212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aluminium loading during therapeutic plasma exchange.
    Monteagudo F; Wood L; Jacobs P; Folb P; Cassidy M
    J Clin Apher; 1987; 3(3):161-3. PubMed ID: 3558340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone histoquantitative findings and histochemical staining reactions for aluminium in chronic renal failure patients treated with haemodialysis fluids containing high and low concentrations of aluminium.
    McClure J; Fazzalari NL; Fassett RG; Pugsley DJ
    J Clin Pathol; 1983 Nov; 36(11):1281-7. PubMed ID: 6630577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aluminum-related bone disease in mild and advanced renal failure: evidence for high prevalence and morbidity and studies on etiology and diagnosis.
    Smith AJ; Faugère MC; Abreo K; Fanti P; Julian B; Malluche HH
    Am J Nephrol; 1986; 6(4):275-83. PubMed ID: 3777036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum aluminium measurements in renal bone disease.
    Lancet; 1983 May; 1(8334):1168-9. PubMed ID: 6133187
    [No Abstract]   [Full Text] [Related]  

  • 17. The desferrioxamine test predicts bone aluminium burden induced by A1(OH)3 in uraemic patients but not mild histological osteomalacia.
    Fournier A; Fohrer P; Leflon P; Moriniere P; Tolani M; Lambrey G; Demontis R; Sebert JL; Van Devyver F; Debroe M
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():371-6. PubMed ID: 3991525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of serum aluminium levels for bone accumulation in haemodialyzed patients.
    Costantini S; Giordano R; Vernillo I; Piccioni A; Zapponi GA
    Ann Ist Super Sanita; 1989; 25(3):457-61. PubMed ID: 2624356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aluminium and bone disease in chronic renal failure.
    Malluche HH
    Nephrol Dial Transplant; 2002; 17 Suppl 2():21-4. PubMed ID: 11904354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of various treatment modalities on aluminium associated bone disease.
    Ihle BU; Buchanan MR; Stevens B; Becker GJ; Kincaid-Smith P
    Proc Eur Dial Transplant Assoc; 1983; 19():195-202. PubMed ID: 6348735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.